Monkeypox RNA Antigen Compositions for Orthopoxvirus Cross-Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for monkeypox and other orthopoxviruses are limited in their efficacy and cross-protection capabilities, and there is a need for improved immunogenic compositions that can effectively prevent or treat monkeypox infections and provide broad-spectrum protection against related viruses.
Innovation Solution
Development of monkeypox antigen constructs, including B cell and T cell antigens, encoded by polyribonucleotides, which induce robust immune responses and cross-protection against orthopoxviruses, utilizing amino acid modifications to enhance stability and immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines are used for monkeypox prevention, then vaccination can be provided, but efficacy and cross-protection capabilities are limited
Solution Approach 1:
The vaccine composition is segmented into multiple distinct antigen components including monkeypox virus antigens and orthopoxvirus antigens. This segmentation allows each antigen to target specific viral proteins and epitopes, enabling both high efficacy against monkeypox and broad cross-protection against related orthopoxviruses through separate immunogenic pathways
Solution Approach 2:
The vaccine composition achieves multi-functionality by incorporating antigens from both monkeypox virus and orthopoxvirus. This universal approach allows a single vaccine formulation to provide protection against multiple related viruses, including variola virus, through shared immunogenic epitopes and cross-reactive immune responses
2Reliability
If polyribonucleotide antigen constructs are used, then robust immune responses are induced, but complexity of antigen construct design increases
Solution Approach 1:
The polyribonucleotide antigen constructs incorporate localized modifications at specific positions within the antigen sequence. These local quality changes include amino acid substitutions at particular epitopic regions to enhance immunogenicity while maintaining overall protein structure and function, thereby achieving robust immune responses without excessive complexity
Solution Approach 2:
The antigen constructs utilize parameter changes in the polyribonucleotide sequence, including codon optimization and amino acid modifications at specific positions. These parameter adjustments enhance translation efficiency and immune recognition while maintaining manageable construct design through systematic modification approaches
Data Source
AI summary
The present disclosure provides pharmaceutical compositions for delivery of monkeypox antigens (e.g., a monkeypox vaccine) and related technologies (e.g., components thereof and/or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more monkeypox antigens or fragments thereof.